Rabie H, et al. - In this prospective, open-label, one-group, one-sequence study, authors assessed 96 young HIV-infected children with tuberculosis in South African provinces to examine the efficacy of lopinavir–ritonavir super-boosting therapy in candidates during rifampicin-based tuberculosis treatment. They prescribed the candidates with standard 4:1 ratio of lopinavir–ritonavir in the absence of rifampicin-based anti-tuberculosis treatment and super-boosting of lopinavir–ritonavir with additional ritonavir twice a day orally to achieve a 1:1 ratio during rifampicin therapy. Overall, they observed positive and safe impacts of super-boosting but with limited preference and poor acceptability. Hence, they recommended its access to improve public health.